Insiders · AMGN

James E. Bradner

EVP, Research and Development at Amgen Inc (AMGN) since December 2023

James E. Bradner has filed 7 insider reports with the SEC since December 2023, as EVP and research and Development at Amgen Inc (AMGN). The latest filing, on May 11, 2026, reports shares withheld for taxes or exercise price at Amgen Inc (AMGN).

Filings
7
Companies
1
Bought on market
None
Sold on market
None

Companies where James E. Bradner is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Amgen Inc logo
AMGN
Amgen Inc
EVP, Research and Developmentsince December 202330,016$457.93May 11, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare James E. Bradner with

Other insiders at the same companies

Questions about James E. Bradner

What is James E. Bradner's role at Amgen Inc?
James E. Bradner reports to the SEC as EVP and research and Development at Amgen Inc (AMGN), according to the latest filing on May 11, 2026.
How many shares does James E. Bradner own?
After the latest filing that states it, James E. Bradner directly owned 30,016 shares of Amgen Inc (AMGN). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has James E. Bradner bought or sold stock recently?
No open-market purchases or sales by James E. Bradner are on file. The filings report shares withheld for taxes or exercise price and grant or award.
How do I get alerts when James E. Bradner files?
Follow James E. Bradner on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by James E. Bradner (SEC CIK 0002005159). Totals count each trade once, skipping amendments whose original is on file, from Dec 20, 2023 on. View on SEC EDGAR